Telix Pharmaceuticals Ltd
ASX:TLX

Watchlist Manager
Telix Pharmaceuticals Ltd Logo
Telix Pharmaceuticals Ltd
ASX:TLX
Watchlist
Price: 25.28 AUD 0.12%
Market Cap: 8.5B AUD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+38%
Revenue
Forecast
+35%
Operating Income
Forecast
+88%
Net Income
Forecast
+97%

Wall Street
Price Targets

TLX Price Targets Summary
Telix Pharmaceuticals Ltd

Wall Street analysts forecast TLX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TLX is 34.81 AUD with a low forecast of 29.43 AUD and a high forecast of 37.8 AUD.

TLX Lowest Forecast
Wall Street Target
29.43 AUD
16% Upside
TLX Average Forecast
Wall Street Target
34.81 AUD
38% Upside
TLX Highest Forecast
Wall Street Target
37.8 AUD
50% Upside
Lowest
Price Target
29.43 AUD
16% Upside
Average
Price Target
34.81 AUD
38% Upside
Highest
Price Target
37.8 AUD
50% Upside
Telix Pharmaceuticals Ltd Competitors:
Price Targets
IMNM
Immunome Inc
185% Upside
TSHA
Taysha Gene Therapies Inc
142% Upside
FYB
Formycon AG
157% Upside
S
688373
Shanghai MicuRx Pharmaceutical Co Ltd
15% Downside
IMNM
Immunome Inc
185% Upside
TSHA
Taysha Gene Therapies Inc
142% Upside
FYB
Formycon AG
157% Upside
S
688373
Shanghai MicuRx Pharmaceutical Co Ltd
15% Downside
VCYT
Veracyte Inc
63% Upside
005690
Pharmicell Co Ltd
41% Upside
SBTX
SkinBioTherapeutics PLC
203% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
37% Upside

Revenue
Forecast

Revenue Estimate
Telix Pharmaceuticals Ltd

For the last 6 years the compound annual growth rate for Telix Pharmaceuticals Ltd's revenue is 299%. The projected CAGR for the next 3 years is 35%.

299%
Past Growth
35%
Estimated Growth
Estimates Accuracy
-22%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Telix Pharmaceuticals Ltd

The compound annual growth rate of Telix Pharmaceuticals Ltd's operating income for the next 3 years is 88%.

N/A
Past Growth
88%
Estimated Growth
Estimates Accuracy
19%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Telix Pharmaceuticals Ltd

The compound annual growth rate of Telix Pharmaceuticals Ltd's net income for the next 3 years is 97%.

N/A
Past Growth
97%
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

See Also

Summary
TLX intrinsic value, competitors valuation, and company profile.
DCF Valuation
TLX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TLX stock valuation using valuation multiples.
Wall Street Estimates
TLX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TLX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TLX's stock price target?
Price Target
34.81 AUD

According to Wall Street analysts, the average 1-year price target for TLX is 34.81 AUD with a low forecast of 29.43 AUD and a high forecast of 37.8 AUD.

What is Telix Pharmaceuticals Ltd's Revenue forecast?
Projected CAGR
35%

For the last 6 years the compound annual growth rate for Telix Pharmaceuticals Ltd's revenue is 299%. The projected CAGR for the next 3 years is 35%.

What is Telix Pharmaceuticals Ltd's Operating Income forecast?
Projected CAGR
88%

The compound annual growth rate of Telix Pharmaceuticals Ltd's operating income for the next 3 years is 88%.

What is Telix Pharmaceuticals Ltd's Net Income forecast?
Projected CAGR
97%

The compound annual growth rate of Telix Pharmaceuticals Ltd's net income for the next 3 years is 97%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 256,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.